A Phase I Study of LY3471851 in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2023-02-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare two different formulations (test & reference) of
LY3471851 in healthy participants. This study will compare how much of each formulation gets
into the blood stream and how long it takes the body to remove it. Information about any side
effects that may occur will also be collected. Participants will remain in the study for
about 12 weeks, after receiving the study drug that is LY3471851.